You are here

Generic Version of Elocon Ointment Approved by FDA

Fort Collins, CO (November 17, 2003) -- Atrix Laboratories, Inc. (NASDAQ NM: ATRX) announced today the company received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for 0.1 percent mometasone furoate ointment.

Atrix's product is the AB-rated generic to Elocon® brand of mometasone furoate ointment USP Ointment 0.1 percent, which is marketed by Schering Plough Corporation. In 2003, branded sales of Elocon are estimated to be approximately $17 million. This newly approved product will be marketed by Geneva Pharmaceuticals, an affiliate of Novartis AG (NYSE: NVS).

"We are pleased to have our second generic topical approved this year," said David R. Bethune, Atrix's chairman and chief executive officer. "This approval, along with our earlier approval for a generic version of EMLA®, represents the beginning steps in building a number of revenue-generating generic dermatology products in the next several years. This product currently has a generic competitor."

Source: Atrix Laboratories, Inc.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs